Newsfeeds Archive - Page 5 of 6

3 minute read

Why G Medical Innovations Shares Are Trading Lower By 35%; Here Are 25 Stocks Moving Premarket

November 21, 8:45 AM

Gainers EUDA Health Holdings Limited (NASDAQ: EUDA) shares rose 88.1% to $8.40 in pre-market trading after merger completed with 8i Acquisition SPAC last week.

AEI

1 minute read

Gritstone bio Shares Jump After Updated Overall Survival Data From Colorectal Cancer Candidate

By Vandana Singh

November 10, 1:09 PM

Gritstone bio Inc (NASDAQ:GRTS) announced updated overall survival (OS) results from its Phase 1/2 study evaluating GRANITE, an individualized vaccine-based immunotherapy…

GRTS

1 minute read

HC Wainwright & Co. Maintains Buy on Gritstone Bio, Lowers Price Target to $7

By Benzinga Newsdesk

November 7, 7:21 AM

HC Wainwright & Co. analyst Sean Lee maintains Gritstone Bio (NASDAQ:GRTS) with a Buy and lowers the price target from $12 to $7.

GRTS

1 minute read

Gritstone Oncology Q3 EPS $(0.35) Up From $(0.36) YoY

By Benzinga Newsdesk

November 3, 5:28 PM

Gritstone Oncology (NASDAQ:GRTS) reported quarterly losses of $(0.35) per share. This is a 2.78 percent increase over losses of $(0.36) per share from the same period last year.

GRTS

5 minute read

Why Sonnet BioTherapeutics Shares Surged Over 66%; Here Are 63 Biggest Movers From Yesterday

By Lisa Levin

November 1, 3:31 AM

Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) climbed 66.4% to close at $1.93 on Monday after the company announced an agreement with Janssen for the evaluation of three Sonnet product candidates.

ACOR

9 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For October 31, 2022

By Benzinga Insights

October 31, 10:13 AM

Upgrades

ABCB

1 minute read

Piper Sandler Initiates Coverage On Gritstone Bio with Overweight Rating, Announces Price Target of $6

By Benzinga Newsdesk

October 31, 5:02 AM

Piper Sandler analyst Edward Tenthoff initiates coverage on Gritstone Bio (NASDAQ:GRTS) with a Overweight rating and announces Price Target of $6.

GRTS

4 minute read

Gritstone Highlights Presentation Of Data From CORAL-BOOST Study

By Benzinga Newsdesk

October 25, 7:09 AM

-- New data from CORAL-BOOST study demonstrate broad and durable immune response; high neutralizing antibody and T cell responses at 6 months post-boost vaccination -- -- Interim results from CORAL-CEPI show good

GRTS